Can IBRX Stock Keep Its Pulse? Institutional Investors Buy In, Retail Hopes For Big Q2 Surprise
Retail traders are watching to see whether ImmunityBio could announce preliminary Q2 revenue, with some speculating that demand for Anktiva could drive sales above $55 million.
Read the full articleStocktwits Inc4h ago
You might also wanna read
Could Roivant Sciences Be a Multibagger Stock Over the Next 5 Years?
Wall Street expects sales to soar as several commercial launches approach.
Bars·3d ago
Is This Biotech Stock a Buy After Its Massive Rally?
This biotech has a powerful growth story, but one competitive threat could reshape the entire investment case before the payoff arrives.
Bars·17h ago
Biogen Is Paying $1 Billion for a Company That Won't Say What It Makes. Here's Why That's Actually Good News for BIIB Investors.
This could be a key move for future growth.
Bars·6d ago
Revolution Medicines Is Up Nearly 140% in 2026. Is the Hot Biotech Stock Still a Buy?
The company recently wowed investors with clinical trial results.
Bars·4d ago
This Stock Is Up 74% This Year: Is It Too Late to Buy?
The biotech is clearly innovative, but sometimes that's not enough.
Bars·1d ago
Dr Reddy's extends slide as semaglutide setback threatens first-mover edge
Supply disruption has cast doubt on Dr Reddy's ability to capitalise on its early lead, with brokerages warning that prolonged delay could a
thehindubusinessline.com·7h ago
Comments
Sign in to join the conversation.
No comments yet. Be the first.